The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents

Heemann, Uwe; Viklický, Ondřej

doi:10.1111/ctr.12044

Cited by 5 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An important mechanism in the regulation of rapamycin involves the inhibition of the progression of cell cycle from the G1 to S phase in T cells (Terada et al ., ). Rapamycin's potent immunosuppressive capacity has led to its approval for use in clinical applications, including solid organ transplantation, by the Food and Drug Administration and European Medicines Evaluation Agency, and it has the potential for application in other areas in which cell proliferation plays a key role (Heemann and Viklicky, ).…”

Section: Introductionmentioning

confidence: 99%

Rapamycin impairs HPD‐induced beneficial effects on glucose homeostasis

Chang

Chiu

et al. 2015

British J Pharmacology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSERapamycin, which is used clinically to treat graft rejection, has also been proposed to have an effect on metabolic syndrome; however, very little information is available on its effects in lean animals/humans. The purpose of this study was to characterize further the effects of the continuous use of rapamycin on glucose homeostasis in lean C57BL6/J mice. EXPERIMENTAL APPROACHMice were fed a high-protein diet (HPD) for 12 weeks to develop a lean model and then were treated daily with rapamycin for 5 weeks while remaining on a HPD. Metabolic parameters, endocrine profiles, glucose tolerance tests, insulin sensitivity index, the expression of the glucose transporter GLUT4 and chromium distribution were measured in vivo. KEY RESULTSLower body weight gain as well as a decreased caloric intake, fat pads, fatty liver scores, adipocyte size and glucose tolerance test values were observed in HPD-fed mice compared with mice fed a high-fat or standard diet. Despite these beneficial effects, rapamycin-treated lean mice showed greater glucose intolerance, reduced insulin sensitivity, lower muscle GLUT4 expression and changes in chromium levels in tissues even with high insulin levels. CONCLUSION AND IMPLICATIONSOur findings demonstrate that continuous rapamycin administration may lead to the development of diabetes syndrome, as it was found to induce hyperglycaemia and glucose intolerance in a lean animal model. AbbreviationsEWAT, epididymal white adipose tissue; HFD, high-fat diet; HPD, high-protein diet; IPGTT, i.p. glucose tolerance test; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; RWAT, retroperitoneal white adipose tissue; SD, standard diet BJP British Journal of Pharmacology

show abstract

Section: Introductionmentioning

confidence: 99%

Rapamycin impairs HPD‐induced beneficial effects on glucose homeostasis

Chang

Chiu

et al. 2015

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Unlike calcineurin inhibitors, belatacept does not exhibit nephrotoxicity and is associated with fewer side effects. [58][59][60] It has been heralded as a breakthrough in kidney transplantation therapeutics. Maintenance immunosuppression with belatacept involves monthly infusions.…”

Section: Belatacept Mechanism Of Action Pharmacokinetics and Pharmaco...mentioning

confidence: 99%

Immunosuppressant Medications in Pregnancy

Saad,

Pacheco,

Saade

2024

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Pregnant patients are often on immunosuppressant medications, most commonly to manage transplantation or autoimmune disorders. Most immunosuppressant agents, including tacrolimus, corticosteroids, azathioprine, and calcineurin inhibitors, are safe during pregnancy and lactation. However, mycophenolic acid is associated with higher risks of birth defects and should be avoided in pregnancy. Tacrolimus, the commonly used drug in transplantation medicine and autoimmune disorders, requires monitoring of serum levels for dose adjustment, particularly during pregnancy. Although no pregnancy-specific therapeutic range exists, the general target range is 5–15 ng/mL, and pregnant patients may require higher doses to achieve therapeutic levels. Adherence to prescribed immunosuppressive regimens is crucial to prevent graft rejection and autoimmune disorder flare-ups. This review aims to provide essential information about the use of immunosuppressant medications in pregnant individuals. With a rising number of pregnant patients undergoing organ transplantations or having autoimmune disorders, it is important to understand the implications of the use of these medications during pregnancy.

show abstract

“…1 представлены препараты, используе-мые для ИСТ в Российской Федерации, и профи-ли их нежелательных явлений (НЯ) [2][3][4].…”

Section: Problematic Aspectsunclassified